AZD1480 - Moligand™, ≥98% , Tyrosine-protein kinase JAK2 inhibitor, CAS No.935666-88-9, Tyrosine-protein kinase JAK2 inhibitor

CAS: 935666-88-9 Cat. No.: A126326 Fórmula: C₁₄H₁₄ClFN₈ Peso molecular: 348.77 Número CE: 641-076-0

GRADE & PURITY Moligand™, ≥98%

Synonyms

5-Chloro-N2-[(1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)-2,4-pyrimidinediamine | 5-Chloro-N2-[(1s)-1-(5-Fluoropyrimidin-2-Yl)ethyl]-N4-(5-Methyl-1h-Pyrazol-3-Yl)pyrimidine-2,4-Diamine | AKOS027322548 | GTPL5933 | AM85979 | BCPP0003

Storage

Store at -20°C

Shipped In

Ice chest + Ice pads

Visão geral

AZD1480 has been used as an inhibitor of janus kinase 2 (JAK2) and signal transducer and activator of transcription 3 (STAT3) in an in vitro cell model of upper gastrointestinal adenocarcinoma. It has also been used in combination with bortezomib to study tumor-associated macrophage-mediated survival of myeloma cells.

Specifications

Sinónimos

5-Chloro-N2-[(1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)-2,4-pyrimidinediamine | 5-Chloro-N2-[(1s)-1-(5-Fluoropyrimidin-2-Yl)ethyl]-N4-(5-Methyl-1h-Pyrazol-3-Yl)pyrimidine-2,4-Diamine | AKOS027322548 | GTPL5933 | AM85979 | BCPP0003

Especificações e pureza

Moligand™, ≥98%

Mecanismos bioquímicos e fisiológicos

AZD1480 demonstrated significant immunoregulatory effects by downregulating T-helper 2 cytokines and chemokines, including IL-13 and thymus- and activation-regulated chemokine, and the surface expression of the immunosuppressive programmed death ligands 1

Condições de armazenamento de armazenamento

Store at -20°C

Enviado em

Ice chest + Ice pads

Este produto requer transporte de cadeia fria. Serviços terrestres e outros serviços econômicos não estão disponíveis.

Grau

Moligand™

Tipo de ação

INHIBITOR

Mecanismo de ação

Tyrosine-protein kinase JAK2 inhibitor

Nota

Toxic, refer to SDS for further information Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.

Pureza

≥98%

Propriedades do produto

ALogP

2.4

Nomes e identificadores

Pubchem Sid

488199394

Pubchem Sid Url

https://pubchem.ncbi.nlm.nih.gov/substance/488199394

Sorrisos canónicos

CC1=CC(=NN1)NC2=NC(=NC=C2Cl)NC(C)C3=NC=C(C=N3)F

IUPAC Name

5-chloro-2-N-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-4-N-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine

InChIKey

PDOQBOJDRPLBQU-QMMMGPOBSA-N

INCHI

1S/C14H14ClFN8/c1-7-3-11(24-23-7)21-13-10(15)6-19-14(22-13)20-8(2)12-17-4-9(16)5-18-12/h3-6,8H,1-2H3,(H3,19,20,21,22,23,24)/t8-/m0/s1

SMILES isoméricas

CC1=CC(=NN1)NC2=NC(=NC=C2Cl)N[C@@H](C)C3=NC=C(C=N3)F

Peso molecular

348.77

Reaxy-Rn

12890501

Reaxys-RN_link_address

https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=12890501&ln=

Taxonomic Classification

Taxonomy Tree

• Kingdom Organic compounds
  • Superclass Organoheterocyclic compounds
    • Classe Diazines
      • Subclass Pyrimidines and pyrimidine derivatives

• Kingdom: Organic compounds
• Superclass: Organoheterocyclic compounds
• Classe: Diazines
• Subclass: Pyrimidines and pyrimidine derivatives
• Intermediate Tree Nodes: Not available
• Direct Parent: Halopyrimidines
• Alternative Parents: Aminopyrimidines and derivatives Imidolactams Aryl fluorides Aryl chlorides Pyrazoles Heteroaromatic compounds Azacyclic compounds Organofluorides Organochlorides Hydrocarbon derivatives Amines
• Molecular Framework: Aromatic heteromonocyclic compounds
• Substituents: Aminopyrimidine - Halopyrimidine - Aryl chloride - Aryl fluoride - Aryl halide - Imidolactam - Azole - Pyrazole - Heteroaromatic compound - Azacycle - Organonitrogen compound - Organofluoride - Organochloride - Organohalogen compound - Hydrocarbon derivative - Organic nitrogen compound - Amine - Aromatic heteromonocyclic compound
• Descrição: This compound belongs to the class of organic compounds known as halopyrimidines. These are aromatic compounds containing a halogen atom linked to a pyrimidine ring. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.
• External Descriptors: Not available

Data sources

1. Djoumbou Feunang Y, Eisner R, Knox C, Chepelev L, Hastings J, Owen G, Fahy E, Steinbeck C, Subramanian S, Bolton E, Greiner R, and Wishart DS. ClassyFire: Automated Chemical Classification With A Comprehensive, Computable Taxonomy. Journal of Cheminformatics, 2016, 8:61.

DOI: 10.1186/s13321-016-0174-y

Alvos associados (humanos)

STAT3 Tchem Signal transducer and activator of transcription 3 (2 Activities)

Discover Target: STAT3

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

JAK3 Tclin Tyrosine-protein kinase JAK3 (1 Activities)

Discover Target: JAK3

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

JAK1 Tclin Tyrosine-protein kinase JAK1 (1 Activities)

Discover Target: JAK1

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

STAT5A Tchem Signal transducer and activator of transcription 5A (2 Activities)

Discover Target: STAT5A

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

NTRK1 Tclin High affinity nerve growth factor receptor (1 Activities)

Discover Target: NTRK1

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

JAK2 Tclin Tyrosine-protein kinase JAK2 (1 Activities)

Discover Target: JAK2

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

ABL1 Tclin Tyrosine-protein kinase ABL (18331 Activities)

Discover Target: ABL1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

EGFR Tclin Epidermal growth factor receptor erbB1 (33727 Activities)

Discover Target: EGFR

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

INSR Tclin Insulin receptor (5558 Activities)

Discover Target: INSR

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

TOP2A Tclin DNA topoisomerase II alpha (6317 Activities)

Discover Target: TOP2A

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

IMPDH2 Tclin Inosine-5'-monophosphate dehydrogenase 2 (1326 Activities)

Discover Target: IMPDH2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PDGFRB Tclin Platelet-derived growth factor receptor beta (5195 Activities)

Discover Target: PDGFRB

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

IGF1R Tclin Insulin-like growth factor I receptor (8605 Activities)

Discover Target: IGF1R

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

DCK Tchem Deoxycytidine kinase (530 Activities)

Discover Target: DCK

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

MAPK11 Tchem MAP kinase p38 beta (2785 Activities)

Discover Target: MAPK11

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

LCK Tclin Tyrosine-protein kinase LCK (9212 Activities)

Discover Target: LCK

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

NQO2 Tchem Quinone reductase 2 (885 Activities)

Discover Target: NQO2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ADK Tchem Adenosine kinase (1481 Activities)

Discover Target: ADK

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

MAPK14 Tchem MAP kinase p38 alpha (12866 Activities)

Discover Target: MAPK14

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

AK2 Tbio Adenylate kinase 2 (264 Activities)

Discover Target: AK2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

GSK3B Tclin Glycogen synthase kinase-3 beta (11785 Activities)

Discover Target: GSK3B

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PRKACB Tchem cAMP-dependent protein kinase beta-1 catalytic subunit (589 Activities)

Discover Target: PRKACB

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PRKCZ Tchem Protein kinase C zeta (2414 Activities)

Discover Target: PRKCZ

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

MAP2K6 Tchem Dual specificity mitogen-activated protein kinase kinase 6 (1284 Activities)

Discover Target: MAP2K6

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

MYLK Tchem Myosin light chain kinase, smooth muscle (1267 Activities)

Discover Target: MYLK

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CSNK1G1 Tchem Casein kinase I gamma 1 (2496 Activities)

Discover Target: CSNK1G1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

FGFR1 Tclin Fibroblast growth factor receptor 1 (9149 Activities)

Discover Target: FGFR1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

STK3 Tchem Serine/threonine-protein kinase MST2 (3069 Activities)

Discover Target: STK3

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PRKAG1 Tchem AMP-activated protein kinase, gamma-1 subunit (254 Activities)

Discover Target: PRKAG1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CSNK1D Tchem Casein kinase I delta (4546 Activities)

Discover Target: CSNK1D

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

MAP2K5 Tchem Dual specificity mitogen-activated protein kinase kinase 5 (650 Activities)

Discover Target: MAP2K5

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

SRC Tclin Tyrosine-protein kinase SRC (10310 Activities)

Discover Target: SRC

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

MAP2K3 Tchem Dual specificity mitogen-activated protein kinase kinase 3 (632 Activities)

Discover Target: MAP2K3

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CDK6 Tclin Cyclin-dependent kinase 6 (1724 Activities)

Discover Target: CDK6

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PRKAG2 Tchem AMP-activated protein kinase, gamma-2 subunit (243 Activities)

Discover Target: PRKAG2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

AKT2 Tchem Serine/threonine-protein kinase AKT2 (4301 Activities)

Discover Target: AKT2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

AKT3 Tchem Serine/threonine-protein kinase AKT3 (3157 Activities)

Discover Target: AKT3

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

GRK2 Tchem G-protein coupled receptor kinase 2 (1019 Activities)

Discover Target: GRK2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PYGB Tchem Brain glycogen phosphorylase (474 Activities)

Discover Target: PYGB

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

AURKB Tchem Serine/threonine-protein kinase Aurora-B (6805 Activities)

Discover Target: AURKB

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

RPS6KA4 Tchem Ribosomal protein S6 kinase alpha 4 (2104 Activities)

Discover Target: RPS6KA4

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

ROCK1 Tclin Rho-associated protein kinase 1 (4723 Activities)

Discover Target: ROCK1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PIM1 Tchem Serine/threonine-protein kinase PIM1 (9629 Activities)

Discover Target: PIM1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PKN2 Tchem Protein kinase N2 (1991 Activities)

Discover Target: PKN2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CSK Tchem Tyrosine-protein kinase CSK (2395 Activities)

Discover Target: CSK

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

JAK3 Tclin Tyrosine-protein kinase JAK3 (8349 Activities)

Discover Target: JAK3

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

RPS6KA5 Tchem Ribosomal protein S6 kinase alpha 5 (3355 Activities)

Discover Target: RPS6KA5

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PRKD3 Tchem Protein kinase C nu (2315 Activities)

Discover Target: PRKD3

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PRKCI Tchem Protein kinase C iota (2821 Activities)

Discover Target: PRKCI

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

SYK Tclin Tyrosine-protein kinase SYK (7372 Activities)

Discover Target: SYK

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PLK1 Tchem Serine/threonine-protein kinase PLK1 (28605 Activities)

Discover Target: PLK1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

JAK1 Tclin Tyrosine-protein kinase JAK1 (8569 Activities)

Discover Target: JAK1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

RPS6KA1 Tchem Ribosomal protein S6 kinase alpha 1 (2796 Activities)

Discover Target: RPS6KA1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

JAK2 Tclin Tyrosine-protein kinase JAK2 (12915 Activities)

Discover Target: JAK2

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

RPS6KA6 Tchem Ribosomal protein S6 kinase alpha 6 (2027 Activities)

Discover Target: RPS6KA6

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

PFKP Tbio Phosphofructokinase platelet type (224 Activities)

Discover Target: PFKP

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Alvos associados (não humanos)

Cdk4 Cyclin-dependent kinase 4 (3 Activities)

Discover Target: Cdk4

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Pygl Liver glycogen phosphorylase (81 Activities)

Discover Target: Pygl

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Prkcd Protein kinase C delta (192 Activities)

Discover Target: Prkcd

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Prkcb Protein kinase C beta (2 Activities)

Discover Target: Prkcb

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Mapk1 MAP kinase ERK2 (650 Activities)

Discover Target: Mapk1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Hdac6 Histone deacetylase 6 (222 Activities)

Discover Target: Hdac6

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Camk2g CaM kinase II gamma (1 Activities)

Discover Target: Camk2g

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Tec Tyrosine-protein kinase TEC (25 Activities)

Discover Target: Tec

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Canis familiaris (36305 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Mus musculus (284745 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Rattus norvegicus (775804 Activities)

Explore this target

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

AIRC Multifunctional protein ADE2 (8 Activities)

Discover Target: AIRC

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

rep Replicase polyprotein 1ab (378 Activities)

Discover Target: rep

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Septin9 Septin-9 (1 Activities)

Discover Target: Septin9

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Acadvl Very long-chain specific acyl-CoA dehydrogenase, mitochondrial (1 Activities)

Discover Target: Acadvl

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Mecanismos de ação

Propriedades químicas e físicas

• Solubilidade: DMSO ≥68mg/mL Water <1.2mg/mL Ethanol ≥4.7mg/mL
• Índice de refração: 1.7
• Ponto de ebulição (°C): ~575.2 °C at 760 mmHg
• Ponto de fusão (°C): 213.39°C
• Peso molecular: 348.760 g/mol
• XLogP3: 2.400
• Hydrogen Bond Donor Count: 3
• Hydrogen Bond Acceptor Count: 8
• Rotatable Bond Count: 5
• Exact Mass: 348.101 Da
• Monoisotopic Mass: 348.101 Da
• Topological Polar Surface Area: 104.000 Ų
• Heavy Atom Count: 24
• Formal Charge: 0
• Complexity: 397.000
• Isotope Atom Count: 0
• Defined Atom Stereocenter Count: 1
• Undefined Atom Stereocenter Count: 0
• Defined Bond Stereocenter Count: 0
• Undefined Bond Stereocenter Count: 0
• The total count of all stereochemical bonds: 0
• Covalently-Bonded Unit Count: 1

Application Protocols

Only information from Product Data may be listed here.

• Tested applications: Not specified for this item; refer to CoA/Spec Sheet.
• Recommended working concentrations/dilutions: Not specified for this item; refer to CoA/Spec Sheet.
• Positive controls/standards: Not specified for this item; refer to CoA/Spec Sheet.

General, non-item-specific guidance:

• Prepare a DMSO master stock (e.g., 10–50 mM), aliquot, and store at −20°C. Thaw an aliquot immediately before use and avoid repeated freeze–thaw.
• Establish concentration–response curves (e.g., 10-point, 3-fold serial dilution) to determine potency in your assay system. Include vehicle controls matching the highest DMSO content.
• Confirm functional effects with orthogonal readouts where possible (e.g., biochemical enzyme assay and a cellular biomarker assay) to reduce the risk of off-target interpretation.

For validated, product-specific protocols, please refer to the batch CoA or contact technical support with the SKU and lot number.

Biological Roles

Item-specific disclosure:

• No target, MoA, or pathway information is specified for this SKU in the provided Product Data. For research use only.

Literature context (general; not a product claim):

• AZD1480 is widely described in the literature as a potent inhibitor of the Janus kinase family (notably JAK1/JAK2), used to interrogate JAK–STAT signaling. Inhibition of JAKs can attenuate STAT phosphorylation, nuclear translocation, and transcriptional activation of cytokine-responsive genes in cell systems.
• Tool-compound use: Researchers often employ AZD1480 or similar scaffolds to dissect cytokine/growth-factor pathways, study feedback regulation, and benchmark new chemical entities targeting the same axis.
• System-level considerations: JAK–STAT intersects with MAPK and PI3K pathways; off-target profiling and orthogonal assays are advised to attribute phenotypes to on-target effects.

Good practice reminders:

• Validate target engagement with proximate biomarkers (e.g., pSTAT Western blot) and time-course experiments.
• Include concentration–response curves and appropriate vehicle controls to quantify potency and window.
• Confirm findings across multiple cell lines or primary cells where feasible, as signaling context can shift apparent potency/selectivity.

Note: The above summarizes commonly cited roles in the scientific literature and should be verified for the specific batch via CoA and internal controls.

Buffer Applications

This product is not a buffering agent and is not used to establish or maintain solution pH.

Practical assay-related notes (general, not item-specific):

• When dosing small-molecule inhibitors into biochemical or cell-based assays, choose a buffer appropriate to the biology (e.g., HEPES or Tris for enzyme assays; PBS or culture medium for cells).
• Maintain consistent organic solvent content (e.g., ≤0.1–0.5% DMSO) across all wells/tubes, including vehicle controls, to avoid solvent-driven artifacts.
• If precipitation occurs upon dilution into aqueous media, consider warming gently to ambient, sonicating briefly, or incorporating solubilizers (e.g., 0.01–0.1% non-ionic surfactant or cyclodextrin), provided they do not interfere with the readout.
• Filter sterilize final solutions for sterile applications using low-protein-binding membranes.

Because item-specific pKa/solubility values are not provided, buffer selection should be guided by small pilot tests to ensure clarity and stability over the intended assay timeframe.

Green Alternatives

Solvent and formulation choices often dominate the environmental profile for bioactive small molecules used in screening.

• Reduce DMSO where possible: Although DMSO is relatively benign, minimizing volume reduces solvent waste and potential biological confounding.
• Greener co-solvents/formulations (general guidance):
  • Aqueous vehicles with solubilizers (e.g., hydroxypropyl-β-cyclodextrin) can enable lower DMSO content at the point of use.
  • Ethanol/water mixtures (≤1–2% EtOH final) may suffice for some assays with fewer downstream disposal constraints than DMF/NMP.
  • PEG-400 or glycerol can serve as co-solvents in certain biochemical contexts; verify assay compatibility.

Comparison (general, not item-specific):

• DMSO: Broad solvency; high assay utility; moderate EHS footprint; aim to keep ≤0.5% v/v in final assay.
• Ethanol: Renewable routes available; faster biodegradation; limited solvency for some heteroaromatics.
• PEG-400: Low volatility; good solvency for lipophilic compounds; viscosity can complicate handling; potential assay interference.
• Cyclodextrin solutions: Water-based; reduce organic solvent use; require optimization to avoid compound inclusion effects on biology.

Operational tips:

• Use high-concentration master stocks to minimize total solvent volume in assays.
• Employ miniaturized screening formats to reduce solvent and compound consumption.
• Segregate and recycle suitable solvent streams per institutional green-chemistry practices.

Because item-specific solubility is not disclosed, screen greener vehicles alongside DMSO to identify acceptable, lower-impact conditions.

Pharmaceutical Uses

For research use only. No medical, diagnostic, or therapeutic use.

• Role in pharma R&D (general, not item-specific): AZD1480 is cited in the literature as a reference scaffold for targeting JAK kinases in discovery biology. In pharmaceutical settings, such compounds are often used as tool molecules for target validation, assay development, and comparative benchmarking against new chemical entities.
• Formulation in research contexts: For in vitro work, DMSO stock solutions are typical. For certain in vivo research models, co-solvent systems (e.g., DMSO/PEG-400/saline) or cyclodextrin vehicles are sometimes explored; all such uses require rigorous internal validation and adherence to institutional policies.
• Pharmacopeial status: Not described in major pharmacopeias for excipient or API use based on the information provided here.
• Manufacturing/quality considerations: If used as a reference or control standard in regulated labs, confirm identity/purity against the batch CoA and establish internal acceptance criteria (e.g., retention time match, purity threshold, potency window) appropriate to your method.

Any mention of mechanism or pathway is provided as literature context only and does not imply suitability for clinical or diagnostic applications.

Physical Properties

Item-specific (from Product Data)

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Physical constants (mp, bp, density, nD, pKa, logP, solubility): Not specified for this item; refer to CoA/Spec Sheet.

General/literature guidance (not item-specific):

• Many kinase-targeted small molecules are crystalline or amorphous solids with limited aqueous solubility and good solubility in high-boiling polar aprotic solvents (e.g., DMSO) and certain organic solvents (e.g., DMF, NMP). Typical working practice is to prepare a concentrated DMSO stock (e.g., 10–50 mM) for assay dilution.
• Thermal properties (melting point, decomposition behavior) and spectroscopic identities (UV–Vis, IR) vary by batch and synthesis route. For AZD1480 specifically, consult primary literature or the batch CoA for exact values.
• Aqueous solubility of heteroaromatic kinase inhibitors can often be improved by pH adjustment, cosolvents, or formulation aids (e.g., cyclodextrins), but such adjustments should be validated experimentally for the specific lot.

Because no definitive physical specifications are provided here, treat any numerical property reported elsewhere as literature-only until verified by the item’s CoA/SDS. When planning experiments, perform small-scale solubility trials in intended assay buffers to confirm compatibility and avoid precipitation artifacts.

Quality and Grades

Item-specific (from Product Data)

• Grade: Moligand™
• Purity: Not specified for this item; refer to CoA/Spec Sheet.

What Moligand™ typically denotes (general explanation):

• Moligand™ indicates a research-grade small-molecule suitable for screening, cheminformatics, and probe-based studies in discovery workflows. Vendors commonly support such materials with identity testing (e.g., LC–MS) and structural confirmation (e.g., 1H NMR). Exact analytical methods and acceptance criteria are batch-dependent.

Analytical expectations and verification (not item-specific):

• Identity: Typically verified by LC–MS and/or HRMS; structure consistency checked against reference spectra. Where available, NMR may be provided.
• Purity: Determined by chromatographic area % (e.g., HPLC or UPLC at a defined wavelength). The exact purity threshold for this lot is not disclosed here—consult the CoA.
• Impurities/residuals: Water content, residual solvents, inorganic residues, or counter-ions may be reported on the CoA when applicable. Absent explicit disclosure, treat as not specified.

For regulated or quantitative applications (e.g., SAR decision-making, biophysical binding assays), we strongly recommend reviewing the batch CoA/Spec Sheet and, if necessary, performing fit-for-purpose incoming QC (orthogonal purity check, counter-ion analysis, and potency benchmarking) prior to use.

Reaction and Applications

This product is a bioactive small molecule intended primarily as a tool compound in discovery research rather than a general-purpose synthetic reagent.

• Not typically used as a reagent in named organic reactions (e.g., cross-couplings, oxidations, reductions). Therefore, conventional synthetic application notes (catalyst choices, stoichiometries) are not applicable.
• Practical research applications (general, literature-based):
  • Employed as a pathway probe in studies interrogating JAK–STAT signaling, where small-molecule inhibition is used to modulate phosphorylation cascades and transcriptional outputs.
  • Utilized in cell-based phenotypic assays, target-validation experiments, and mechanism-of-action studies that rely on controlled, reversible inhibition.
  • Benchmarking/positive-control role in biochemical inhibition assays to calibrate assay performance (IC50 window, signal-to-background) when investigating related chemical series.
• Experimental considerations (general):
  • Prepare and handle concentrated DMSO stocks; verify absence of precipitation upon dilution into assay media.
  • Include DMSO vehicle controls and, where appropriate, orthogonal readouts (e.g., target phosphorylation by Western blot vs. reporter assays) to confirm on-pathway effects.

Note: The points above are literature/general practice and not item-specific claims. For this SKU, no manufacturer-verified application set is provided; please consult the CoA/SDS and validate conditions in your laboratory context.

Reaction Conditions

Conventional reaction-condition guidance is not applicable because this product is intended as a bioactive tool compound rather than as a reaction reagent or catalyst.

Operational conditions relevant to research use (general, not item-specific):

• Stock solution preparation: Dissolve in anhydrous DMSO to 10–50 mM, vortex, and, if needed, sonicate briefly. Filter through a 0.22 μm PTFE filter if particulate remains.
• Assay dosing: Dilute into pre-equilibrated assay buffer or culture media while maintaining consistent final DMSO across samples (commonly ≤0.1–0.5% v/v). Mix thoroughly to avoid local supersaturation and precipitation.
• Stability checks: Monitor for precipitation, color change, or potency drift over the assay period. For multi-day studies, prepare fresh dilutions daily from frozen aliquots.
• Light/moisture: Protect from prolonged light exposure and moisture ingress unless specific stability data indicate robustness.

If your use case truly requires chemical transformation of this compound (e.g., prodrug derivatization for internal research), consult primary literature for the scaffold’s synthesis to infer compatible conditions, and perform small-scale feasibility tests with appropriate analytical follow-up (LC–MS, NMR).

Safety and Handling

Item-specific (from Product Data)

• GHS Classification: Not specified for this item; refer to SDS.
• Signal Word: Not specified for this item; refer to SDS.
• Hazard Statements (H-Statements): Not specified for this item; refer to SDS.
• Pictograms: Not specified for this item; refer to SDS.
• Storage Conditions: Store at -20°C.
• Shipped In: Ice chest + Ice pads.

General laboratory precautions (not item-specific):

• Handle in a fume hood with appropriate PPE: lab coat, safety glasses, and suitable gloves (e.g., nitrile). Avoid inhalation of dust or aerosols and prevent skin/eye contact. Wash thoroughly after handling.
• Avoid contaminating skin with DMSO solutions, which can enhance dermal transport of solutes. Clean minor spills with absorbent material; for larger spills, evacuate area and follow institutional procedures.
• Incompatibilities: Strong oxidizers and strong acids/bases may cause degradation for many heteroaromatic drug-like molecules; segregate accordingly. Protect from moisture and prolonged light exposure unless stability is documented.
• First aid (overview; defer to SDS): If inhaled—move to fresh air; if on skin—wash with soap/water; if in eyes—rinse cautiously with water for several minutes; if ingested—rinse mouth and seek medical attention. Provide SDS to responders.

Always consult the product’s SDS for authoritative hazard classification, exposure controls, disposal guidance, and transportation information. For research use only.

Solvent Selection

Item-specific (from Product Data)

• No solvent preferences are specified for this item.

General guidance for kinase-inhibitor-like small molecules (not item-specific):

• Primary stock solvent: DMSO is typically preferred due to broad solvating power and assay compatibility. Prepare concentrated stocks (e.g., 10–50 mM) and store as aliquots at −20°C to minimize freeze–thaw.
• Assay dilution: Dilute DMSO stocks into buffer (e.g., PBS, HEPES, or assay-specific buffer) to reach the desired final concentration while keeping DMSO ≤0.1–0.5% v/v to limit effects on cells/enzymes.
• Alternative solvents: DMF or NMP can dissolve challenging solids but may be less biocompatible; ethanol (with Tween-80 or PEG-400) can be acceptable in some biochemical settings. Validate for your assay.
• Solubility enhancers: Hydroxypropyl-β-cyclodextrin, PEG-400, or co-solvent systems can improve apparent solubility and reduce precipitation upon aqueous dilution.

Comparison (general considerations):

• DMSO: Excellent solvency; widely used; can affect membrane permeability and some enzyme kinetics at >0.5–1%.
• Ethanol: Lower solvency for many heteroaromatics; higher assay tolerability at similar percentages for some systems.
• PEG-400: Formulation aid for in vivo research; viscous; may interfere with certain readouts.

Because item-specific solubility data are not provided, perform a small solubility and compatibility screen in the intended assay matrix before committing to larger experiments.

Storage and Reconstitution

Item-specific (from Product Data)

• Storage Conditions: Store at -20°C.
• Shipping: Ice chest + Ice pads.

Not specified for this item; refer to CoA/Spec Sheet

• Exact stability limits, shelf life, and freeze–thaw tolerance.
• Recommended reconstitution solvent and maximum stock concentration.

General best practices for small-molecule tool compounds (not item-specific):

• Reconstitution: Dissolve in anhydrous DMSO to make a concentrated stock (commonly 10–50 mM). Vortex to clarity; brief sonication may help. If particles persist, filter through a 0.22 μm PTFE syringe filter.
• Aliquoting: Dispense single-use aliquots (e.g., 10–50 μL) in amber vials or PCR tubes to minimize freeze–thaw and light exposure.
• Storage: Keep aliquots tightly sealed at −20°C in desiccated, light-protected conditions. Avoid frost-free freezers that cycle temperatures.
• Use: Thaw an aliquot immediately before use, keep on ice during setup, and promptly return or discard any unused thawed material per your lab’s practices. Do not refreeze partially used aliquots unless stability has been established.
• Aqueous solutions: Prepare immediately before use; many hydrophobic inhibitors can precipitate or degrade in aqueous media over time.

Always prioritize the batch CoA/SDS for lot-specific instructions and stability data. For research use only.

Structure and Identity

Item-specific (from Product Data)

• SKU: A126326
• Product Name: AZD1480
• CAS: 935666-88-9
• PubChem CID: 16659841
• InChIKey: 274619 (as provided)
• SMILES: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular Formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.

General/literature context (not item-specific):

• AZD-series compounds are small-molecule kinase inhibitors developed for pathway interrogation in discovery biology. AZD1480 is widely cited in the literature as a Janus kinase (JAK) pathway tool compound. Specific structural drawings and stereochemical descriptors should be taken from primary references or the Certificate of Analysis (CoA).

Structural description (general):

• As a typical ATP-competitive kinase inhibitor scaffold, literature precedents often feature heteroaromatic motifs capable of forming hinge-binding hydrogen bonds, plus substituents that engage selectivity pockets. Without an item-specific structure disclosure here, please consult the CoA or trusted databases for the exact 2D/3D structure, ring systems, functional groups, and any stereogenic elements applicable to AZD1480.

Note: Identity confirmation for screening compounds is commonly supported by LC–MS and 1H NMR. Always verify against the batch-specific CoA prior to use in critical studies.

Synthetic Utility

This item is supplied as a finished bioactive small molecule and is not typically employed as a synthetic building block.

• Not commonly used as a coupling partner, electrophile, nucleophile, or catalyst in standard organic methodology. Therefore, traditional synthetic-utility guidance (e.g., reactivity patterns, protecting-group strategies) is not applicable.
• Medicinal chemistry context (general): Related scaffolds are sometimes derivatized to explore structure–activity relationships (SAR). If undertaking analog synthesis, typical operations might include heteroaryl substitutions, amide/urea formation, or heterocycle elaboration—but these activities pertain to new syntheses rather than using the supplied compound as a reagent.
• Stability considerations (general): Heteroaromatic kinase inhibitors can contain functionalities sensitive to strong acids/bases, prolonged heating, or photolysis. Any planned chemical modification should begin with a stability screen to map tolerant conditions.

Conclusion: Treat AZD1480 primarily as a probe/tool compound. For synthetic campaigns, consult primary literature for enabling routes to the core scaffold rather than attempting to repurpose the finished molecule as a reagent.

Target Specificity

Only information from Product Data may be listed here.

• Target/Pathway: Not specified for this item; refer to CoA/Spec Sheet.
• Species reactivity: Not specified for this item; refer to CoA/Spec Sheet.
• Assay-validated selectivity panel: Not specified for this item; refer to CoA/Spec Sheet.

Note: Although AZD1480 is often discussed in the literature in the context of JAK–STAT signaling, no target specificity is provided in this listing. Users should consult the batch CoA and verify target engagement in their own systems.

Perguntas frequentes

What is the purity of this product?

This product is supplied at ≥98% purity (chemical assay). Lot-specific values are stated on the Certificate of Analysis.